JPWO2014192853A1 - 環状デバイス - Google Patents
環状デバイス Download PDFInfo
- Publication number
- JPWO2014192853A1 JPWO2014192853A1 JP2015519924A JP2015519924A JPWO2014192853A1 JP WO2014192853 A1 JPWO2014192853 A1 JP WO2014192853A1 JP 2015519924 A JP2015519924 A JP 2015519924A JP 2015519924 A JP2015519924 A JP 2015519924A JP WO2014192853 A1 JPWO2014192853 A1 JP WO2014192853A1
- Authority
- JP
- Japan
- Prior art keywords
- annular device
- annular
- substantially circular
- present
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004087 cornea Anatomy 0.000 claims abstract description 14
- 210000003786 sclera Anatomy 0.000 claims description 11
- 210000005252 bulbus oculi Anatomy 0.000 abstract description 23
- 239000000178 monomer Substances 0.000 description 43
- 239000003814 drug Substances 0.000 description 41
- 229940079593 drug Drugs 0.000 description 41
- 239000000017 hydrogel Substances 0.000 description 15
- 210000001508 eye Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 125000004122 cyclic group Chemical group 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 238000006116 polymerization reaction Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 206010042674 Swelling Diseases 0.000 description 6
- -1 hydroxypropyl Chemical group 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 239000010409 thin film Substances 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001328 optic nerve Anatomy 0.000 description 4
- 239000003505 polymerization initiator Substances 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000026062 Tissue disease Diseases 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 125000003010 ionic group Chemical group 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013269 sustained drug release Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MPXHLFZVRCWKOH-UHFFFAOYSA-N (2-benzoyl-4-tert-butylphenyl) prop-2-enoate Chemical compound CC(C)(C)c1ccc(OC(=O)C=C)c(c1)C(=O)c1ccccc1 MPXHLFZVRCWKOH-UHFFFAOYSA-N 0.000 description 1
- DSTUKHPLWATFCG-UHFFFAOYSA-N (2-benzoylphenyl) prop-2-enoate Chemical compound C=CC(=O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 DSTUKHPLWATFCG-UHFFFAOYSA-N 0.000 description 1
- MJYFYGVCLHNRKB-UHFFFAOYSA-N 1,1,2-trifluoroethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(F)(F)CF MJYFYGVCLHNRKB-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical compound CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- QNRSQFWYPSFVPW-UHFFFAOYSA-N 5-(4-cyanobutyldiazenyl)pentanenitrile Chemical compound N#CCCCCN=NCCCCC#N QNRSQFWYPSFVPW-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- YIVJZNGAASQVEM-UHFFFAOYSA-N Lauroyl peroxide Chemical compound CCCCCCCCCCCC(=O)OOC(=O)CCCCCCCCCCC YIVJZNGAASQVEM-UHFFFAOYSA-N 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- 206010038903 Retinal vascular occlusion Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- DAKWPKUUDNSNPN-UHFFFAOYSA-N Trimethylolpropane triacrylate Chemical compound C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C DAKWPKUUDNSNPN-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- OQHMGFSAURFQAF-UHFFFAOYSA-N [2-hydroxy-3-(2-methylprop-2-enoyloxy)propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)COC(=O)C(C)=C OQHMGFSAURFQAF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 1
- 201000006321 fundus dystrophy Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- OMNKZBIFPJNNIO-UHFFFAOYSA-N n-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=O)CC(C)(C)NC(=O)C=C OMNKZBIFPJNNIO-UHFFFAOYSA-N 0.000 description 1
- RQAKESSLMFZVMC-UHFFFAOYSA-N n-ethenylacetamide Chemical compound CC(=O)NC=C RQAKESSLMFZVMC-UHFFFAOYSA-N 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000007870 radical polymerization initiator Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 231100000330 serious eye damage Toxicity 0.000 description 1
- 125000005401 siloxanyl group Chemical group 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
- G02C7/048—Means for stabilising the orientation of lenses in the eye
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
- G02C7/047—Contact lens fitting; Contact lenses for orthokeratology; Contact lenses for specially shaped corneae
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
- Adornments (AREA)
Abstract
Description
本発明に係る環状デバイスは、強膜表面に装用するためのデバイスであり、角膜を露出させる開口部を有し、かつ、内縁部及び外縁部の間の中間部の後面に略周回の溝が1つ又は複数あることを特徴とする。
本発明における「後面」とは、本発明の環状デバイスを眼の強膜表面に装用する場合、強膜表面と接する本発明の環状デバイスの一方の面をいう。この場合、強膜表面と接せずに、瞼の裏や外気と触れ合う本発明の環状デバイスの他方の面を前面という。
本発明の環状デバイスは、ハイドロゲルからなることが好ましい。ハイドロゲルとしては、親水性モノマーを用いて製造されたハイドロゲル、親水性モノマーに疎水性モノマー若しくは架橋性モノマー又はその両方を添加して製造されたハイドロゲルなどが挙げられる。
本発明の環状デバイスは、薬物を含有させることができる。薬物としては、例えば、溶媒に溶解し得る薬物が使用され、後眼部組織疾患の予防及び/又は治療を目的とする薬物であることが好ましい。
本発明の環状デバイスは、これまでに知られている方法、例えば、キャストモールド製法やレースカット製法により製造することができるが、本発明の環状デバイスを製造する方法はこれらに限定されない。キャストモールド製法は、重合後に所望の形状(環状)となるように予め設計された成形型を用いて、成形型中で重合反応を行い、環状デバイスを得る製法である。レースカット製法は、まずブロック状の重合体を得て、次いでこのブロック体から環状デバイスの形状に切削、研磨などを行う製法である。
まず、親水性モノマー或いは親水性モノマーに疎水性モノマー若しくは架橋性モノマー又はその両方を添加したモノマーの混合物に、重合開始剤を添加し、攪拌、溶解させ、モノマー混合液を得る。
まず、重合後の形状がブロック状となる成形型を用いて、キャストモールド製法と同様の方法により、ブロック状の重合体を得て、次いで得られたブロック体から切削にて強角膜レンズを作製する。得られた強角膜レンズに所望の大きさの開口部を開け、周辺部を研磨加工して環状デバイスを得る。このとき開口部をまず空けておいてからレンズ状のデバイスに切削することも可能である。
本発明の環状デバイスは、強膜表面上、特に強膜表面を被覆している球結膜の部分に装用する。装用には専用の補助具を用いることもできる。また、本発明の環状デバイスを薬物徐放用として用いる場合においては、本発明の環状デバイスによる薬物の投与量はその種類によっても異なるが、通常1回に1μg〜100mg程度である。また、本発明の環状デバイスによる薬物の投与回数は、症状、年齢などによって適宜選択することができるが、1日1〜数回(例えば、1〜6回)又は数日から数ヶ月に1回デバイスを眼に装用すればよい。
親水性モノマーとして2−ヒドロキシエチルメタクリレート99g、架橋性モノマーとしてエチレングリコールジメタクリレート1g、重合開始剤として2,2’−アゾビスイソブチロニトリル0.15gを混合した後、重合後に表1に示す外径、内径、厚み及び/又は溝を有する実施例1〜6及び比較例1の構造になるように予め設計された成形型中で加熱重合を行った(窒素雰囲気下、室温〜100℃に昇温、40時間)。得られた膨潤前のデバイスを生理食塩水中で60℃、30分間加熱することで膨潤させ、高圧蒸気滅菌を施して環状デバイスとした。
4名の被験者に実施例1〜6及び比較例1の環状デバイスを装用させた後、以下に示す条件に従い装用感を評価した。また、環状デバイスを装用した被験者について、細隙灯顕微鏡(スリットランプマイクロスコープ SM−70/(株)タカギセイコー社製)にて観察し、以下に示す条件に従い環状デバイスの眼球上での安定性を評価した。
+:比較例より実施例の方が良好である。
+/−:実施例と比較例に違いがない
−:実施例より比較例の方が良好である。
+:比較例より実施例の方が良好である。
+/−:実施例と比較例に違いがない
−:実施例より比較例の方が良好である。
B:内径
C:内縁部の厚み
D:中間部の厚み
E:外縁部の厚み
F:略周回の溝の深さ
G:略周回の溝の幅
1:外縁点
2:内縁点
3:中間部
4:二等分点
5a〜r:略周回の溝
6:中心点
7a〜b:中点
8a〜b:三等分点
9:仮想円
10:内縁部
11:外縁部
13:開口部
14:湾曲薄膜片
15:外周部
20a〜i:環状デバイス
Claims (4)
- 角膜を露出させる開口部を有し、かつ、内縁部及び外縁部の間の中間部の後面に略周回の溝が1つ又は複数あることを特徴とする、強膜表面に装用するための環状デバイス。
- 前記略周回の溝が2つあることを特徴とする、請求項1に記載の環状デバイス。
- 前記略周回の溝が3つあることを特徴とする、請求項1に記載の環状デバイス。
- 前記中間部が最大厚みを有することを特徴とする、請求項1に記載の環状デバイス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013113962 | 2013-05-30 | ||
JP2013113962 | 2013-05-30 | ||
PCT/JP2014/064232 WO2014192853A1 (ja) | 2013-05-30 | 2014-05-29 | 環状デバイス |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2014192853A1 true JPWO2014192853A1 (ja) | 2017-02-23 |
JP6348111B2 JP6348111B2 (ja) | 2018-06-27 |
Family
ID=51988876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015519924A Active JP6348111B2 (ja) | 2013-05-30 | 2014-05-29 | 環状デバイス |
Country Status (9)
Country | Link |
---|---|
US (1) | US9921419B2 (ja) |
EP (1) | EP3005995B1 (ja) |
JP (1) | JP6348111B2 (ja) |
CN (1) | CN105392455B (ja) |
BR (1) | BR112015029651A8 (ja) |
CA (1) | CA2912165C (ja) |
ES (1) | ES2654636T3 (ja) |
RU (1) | RU2673383C2 (ja) |
WO (1) | WO2014192853A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10786959B2 (en) * | 2016-07-18 | 2020-09-29 | Johnson & Johnson Vision Care, Inc | Mold for contact lens with non-rotationally symmetric rim or edge |
JP2018140969A (ja) * | 2017-02-28 | 2018-09-13 | 国立大学法人北海道大学 | 後眼部疾患治療用環状デバイス |
JP6861413B2 (ja) * | 2017-02-28 | 2021-04-21 | 国立大学法人北海道大学 | 角膜上皮疾患の予防または治療用の環状デバイス |
JP6501097B1 (ja) * | 2018-03-30 | 2019-04-17 | 真一 芦田 | 薬剤供給眼用器具 |
JP6501096B1 (ja) * | 2018-03-30 | 2019-04-17 | 真一 芦田 | 薬剤供給眼用器具 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5009497A (en) * | 1987-11-12 | 1991-04-23 | Cohen Allen L | Contact lenses utilizing keel orientation |
WO2005121874A1 (en) * | 2004-06-08 | 2005-12-22 | Siris-K Corporation | Tear groove hard contact lens |
WO2010092735A1 (ja) * | 2009-02-10 | 2010-08-19 | 千寿製薬株式会社 | リング状デバイス |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4484922A (en) | 1981-06-25 | 1984-11-27 | Rosenwald Peter L | Occular device |
US4640594A (en) * | 1982-01-07 | 1987-02-03 | Richard Berger | Tear pump contact lens |
DE3377535D1 (en) * | 1982-10-27 | 1988-09-01 | Pilkington Plc | Bifocal contact lens comprising a plurality of concentric zones |
US5120121A (en) * | 1988-07-21 | 1992-06-09 | Allergan, Inc. | Colored lens |
IL116654A (en) | 1996-01-02 | 1999-08-17 | Holo Or Ltd | Monofocal contact lens |
FR2855761B1 (fr) * | 2003-06-03 | 2006-02-24 | Optis France Sa | Dispositif oculaire de delivrance variable de principes actifs par iontophorese |
AU2004297967C1 (en) * | 2003-12-05 | 2011-10-27 | Innolene Llc | Improved ocular lens |
US7300464B2 (en) * | 2004-09-30 | 2007-11-27 | Alcon, Inc. | Intraocular lens |
RU48763U1 (ru) * | 2005-04-11 | 2005-11-10 | Уфимский научно-исследовательский институт глазных болезней | Интраокулярная линза |
US8099162B2 (en) * | 2005-11-29 | 2012-01-17 | Eyegate Pharma, S.A.S. | Ocular iontophoresis device |
US7878650B2 (en) * | 2006-06-29 | 2011-02-01 | Fritsch Michael H | Contact lens materials, designs, substances, and methods |
US20090303432A1 (en) * | 2007-01-16 | 2009-12-10 | Menicon Co., Ltd. | Contact Lens and Method of Producing Contact Lens |
WO2010036966A1 (en) * | 2008-09-26 | 2010-04-01 | The Cleveland Clinic Foundation | Apparatus and method for delivering a therapeutic agent to ocular tissue |
IN2012DN02153A (ja) * | 2009-08-13 | 2015-08-07 | Acufocus Inc | |
US20110149229A1 (en) * | 2009-12-17 | 2011-06-23 | Pierre Gerligand | Contact lenses with stabilization features |
KR101371685B1 (ko) * | 2012-10-30 | 2014-03-10 | 김선호 | 치료용 콘택트렌즈 |
-
2014
- 2014-05-29 US US14/890,871 patent/US9921419B2/en active Active
- 2014-05-29 CA CA2912165A patent/CA2912165C/en active Active
- 2014-05-29 JP JP2015519924A patent/JP6348111B2/ja active Active
- 2014-05-29 RU RU2015156503A patent/RU2673383C2/ru not_active IP Right Cessation
- 2014-05-29 BR BR112015029651A patent/BR112015029651A8/pt not_active Application Discontinuation
- 2014-05-29 ES ES14804437.3T patent/ES2654636T3/es active Active
- 2014-05-29 CN CN201480031266.0A patent/CN105392455B/zh active Active
- 2014-05-29 WO PCT/JP2014/064232 patent/WO2014192853A1/ja active Application Filing
- 2014-05-29 EP EP14804437.3A patent/EP3005995B1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5009497A (en) * | 1987-11-12 | 1991-04-23 | Cohen Allen L | Contact lenses utilizing keel orientation |
WO2005121874A1 (en) * | 2004-06-08 | 2005-12-22 | Siris-K Corporation | Tear groove hard contact lens |
WO2010092735A1 (ja) * | 2009-02-10 | 2010-08-19 | 千寿製薬株式会社 | リング状デバイス |
Also Published As
Publication number | Publication date |
---|---|
CN105392455B (zh) | 2018-04-06 |
RU2015156503A3 (ja) | 2018-03-26 |
RU2673383C2 (ru) | 2018-11-26 |
RU2015156503A (ru) | 2017-07-05 |
BR112015029651A2 (pt) | 2017-07-25 |
CA2912165C (en) | 2021-04-06 |
CA2912165A1 (en) | 2014-12-04 |
ES2654636T3 (es) | 2018-02-14 |
EP3005995B1 (en) | 2017-12-20 |
EP3005995A1 (en) | 2016-04-13 |
US20160103336A1 (en) | 2016-04-14 |
WO2014192853A1 (ja) | 2014-12-04 |
US9921419B2 (en) | 2018-03-20 |
EP3005995A4 (en) | 2017-01-18 |
JP6348111B2 (ja) | 2018-06-27 |
BR112015029651A8 (pt) | 2018-04-03 |
CN105392455A (zh) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5530371B2 (ja) | リング状デバイス | |
JP6348111B2 (ja) | 環状デバイス | |
US20170192251A1 (en) | Contact lens | |
SG173736A1 (en) | Hydrogel contact lens for sustained drug release and drug release method using hydrogel contact lens for sustained drug release | |
US10668157B2 (en) | Anionic drug-containing medical device | |
JP6861413B2 (ja) | 角膜上皮疾患の予防または治療用の環状デバイス | |
JP2018140969A (ja) | 後眼部疾患治療用環状デバイス | |
TWI796497B (zh) | 含有陰離子性藥劑之眼用器材 | |
JP2004018472A (ja) | 薬剤徐放可能ヒドロゲル材料 | |
JP6687825B2 (ja) | 眼用レンズおよび眼用レンズを用いた結像方法 | |
KR20220096403A (ko) | 약물의 서방출 특성을 갖는 콘택트렌즈 및 이의 제조방법 | |
JP2011167992A (ja) | 環状医療具の成形型及びこの成形型を用いて成形された環状医療具 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170329 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180313 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180425 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180529 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180530 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6348111 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |